Marine Compounds and Cancer 2020

• Andere auteurs: Honecker, Friedemann (Redacteur), Dyshlovoy, Sergey A. (Redacteur)
• Formaat: Elektronisch Hoofdstuk
• Taal: Engels
• Gepubliceerd in: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Onderwerpen: Medicine; apoptosis; fucoidan; hepatocellular carcinoma; reactive oxygen species; 3-alkylpyridinium polymers; nicotine; nicotinic acetylcholine receptor; non-small cell lung carcinoma; melanoma; sinulariolide; proteomic; mitochondria; caspase cascade; marine fungus; sediment; anthranilic acid; Penicillium paneum; cytotoxicity; dibromotyrosine; mitochondrial dysfunction; oxidative stress; topoisomerase; epigonal organ; bonnethead shark; Jurkat; tumor cell line; hippuristanol; PEL; AP-1; STAT3; Akt; colorectal cancer; marine mollusc; brominated indoles; shrimp; chemoprevention; fatty acids; carotenoids; cancer; nanoparticle; osteosarcoma; lung metastasis; elisidepsin; lipid rafts; hydroxylated lipids; fatty acid 2-hydroxylase; cooperative binding; membrane permeabilization; marine organisms; polysaccharides; anticancer; anticarcinogenic; mechanisms of action; fumigaclavine C; anti-proliferation; mitochondrial pathway; anti-cancer; anti-proliferative; carotenoid; cell cycle arrest; fucoxanthin; azoxymethane; bioactive natural product; isatin; in vivo model; Marthasterias glacialis L.; palmitic acid; ER-stress; CHOP; Antibody Drug Conjugates (ADCs); marine antitumor agents; clinical trials; approved antitumor agents; AD0157; angiogenesis; marine drug; pyrrolidinedione; secondary metabolites; cancer preventive; chemopreventive; trabectedin; plitidepsin; tumor-associated macrophages; tumor microenvironment; preclinical; anticancer immunity; antiangiogenesis; fascaplysin; cyclin-dependent kinase; small cell lung cancer; camptothecin; poly(ADP-ribose)-polymerase inhibitor; breast cancer; seaweed; therapeutic compounds; autophagy; marine drugs; autophagy inhibitors; autophagy inducers; macrolide; programmed cell death; energy stress; araguspongine C; c-Met; HER2; gemcitabine; pazopanib; phase I; safety; soft tissue sarcoma; pachastrissamine; jaspine B; carbocyclic analogue; sphingosine kinase inhibitor; molecular modeling; ET-743; DNA minor groove binder; soft tissue sarcoma; chemotherapy; bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM); anti-metastatic activity; cell adhesion; β1-integrin; FAK; BEL-7402 cell; triterpene glycosides; sea cucumbers; antitumor activities; arrest of cell cycle; antibacterial; marangucyclines; deep-sea; Streptomyces sp. SCSIO 11594; LS-1; SNU-C5/5-FU; TGF-β signaling; carcinoembryonic antigen; kalkitoxin; Moorea producens; mitochondria toxin; VEGF; angiogenesis inhibitor; hypoxia-inducible factor-1; HIF-1; Lyngbya majuscula; marine metabolites; SZ-685C; nonfunctioning pituitary adenomas; Ecklonia cava; phlorotannins; dieckol; migration; sipholenol A; ABC transporter; multidrug resistance; P-gp/ABCB1; BCRP/ABCG2; MRP1/ABCC1; marine natural products; glioblastoma; xyloketal B; proliferation; TRPM7; marine compound; ribosomal protein genes; snoRNA; FAU; RPS30; SNORA62; evolution; Porifera; n/a; Penicillium brevicompactum; Brevianamide; Mycochromenic acid derivative; antifouling; Caribbean sponge; plakortide; endoperoxide; leukemia; multi-drug resistant leukemia; Sarcophyton ehrenbergi; soft coral; terpenes; cembranoids; cytotoxic activity; molecular docking; uveal melanoma; oxidative stress; virtual screening; Topo I inhibitor; low toxic; natural product; Ulva fasciata; selenium-containing polysaccharide-protein complex; pseudopterosin; NF-κB; p65; inflammation; cytokine release; IL-6; TNFα; MCP-1; glucocorticoid receptor; paulomycins; Micromonospora; antitumor; Cantabrian Sea-derived actinobacteria; puupehenones; sponges; antiangiogenic; antitumoral; porifera/sponge; cancer genes; molecular oncology; bromophenol; molecular mechanisms; cell cycle; PI3K/Akt; p38/ERK; ROS; human lung cancer; glycosaminoglycans; antiproliferative; heparan sulphate; gliotoxin; NSCLC; adriamycin resistance; Sepia ink polysaccharides; antitumour; chemosensitization; anticoagulation; sea anemone; drug discovery; endothelial cells; RGD motif; kunitz type inhibitor; prostate cancer; antioxidant; natural marine compounds; marine biotechnology; microalgae; marine sponges; Aeroplysinin; Isofistularin; pheochromocytoma and paraganglioma; metastasis; cancer progression; cell adhesion molecules; integrin β1; hypoxia; phycocyanin; non-small cell lung cancer; NF-κB signaling; marine-derived drugs; bioanalysis; chromatography; manzamine A; epithelial-mesenchymal transition; lung cancer; circulating tumor cells; signal transduction; cisplatin; Lampetra morii; buccal gland; cystatin F; anti-angiogenesis; cystatin superfamily; Antimicrobial peptide (AMP); Tilapia piscidin 4 (TP4); non-small cell lung cancer (NSCLC); itampolin A; FBDD; p38α; novel inhibitor; tetracenomycin X; cyclin D1; proteasomal degradation; p38; c-JUN; λ-carrageenan; heparanase; anticoagulant; depolymerisation; cell migration; Aspergillus; naphthopyrones; endophytic fungus; Leathesia nana; mangrove-derived actinomycete; ansamycins; divergolides; apoptosis-inducing activity; actinomycin; EMT; invasion; low molecular weight fucoidan extract; N-Ras; neuroblastoma-rat sarcoma; Cancer; programmed cell death-ligand 1; programmed cell death-ligand 2; human sarcoma cell line (HT1080 cells); human normal diploid fibroblast (TIG-1 cells); chimera; chemical conjugation; anticancer agent; hybridization; α9-nicotinic acetylcholine receptors (nAChRs); breast cancer cells; αO-conotoxin GeXIVA; targeted therapy; gorgonian; Leptogorgia; humulane sesquiterpenoids; anticancer activity; 12-deacetyl-12-epi-scalaradial; HeLa cells; Nur77; MAPK/ERK pathway; Mycalin A; C15 acetogenins; synthetic analogues; antiproliferative activity; A375 and HeLa cell lines; polyoxygenated steroids; sponge; Haliclona gracilis; Thalassia testudinum; thalassiolin B; polyphenols; CYP1A1; benzo[a]pyrene; JNK1/2; natural products; synergism; A549 cells; cytoskeleton; P2X7 receptor; pollution; anti-angiogenic; gene expression; HSP90; inhibitor
• Online toegang: DOAB: download the publication; DOAB: description of the publication

Samenvatting

The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.

Fysieke beschrijving

1 electronic resource (480 p.)

ISBN

books978-3-0365-0631-9
9783036506302
9783036506319

Toegang

Open Access